ADC Therapeutics and Freenome enter biomarker development collaboration

This article was originally published here

ADC Therapeutics is currently evaluating ADCT-402 in a pivotal Phase II clinical trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Freenome’s platform will characterize

The post ADC Therapeutics and Freenome enter biomarker development collaboration appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply